Device Trial Radar · NCT07444320
Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Feb 12, 2026
Primary completion
Feb 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Mar 2, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, prospective, single-arm, feasibility study to evaluate the safety and effectiveness of the waveforms being delivered using the FARAPULSE PFA System in patients with Paroxysmal Atrial Fibrillation (PAF) and Persistent Atrial Fibrillation (PersAF).
Conditions
- Paroxysmal Atrial Fibrillation
- Persistent Atrial Fibrillation
Interventions
FARAPULSE™ Pulsed Field Ablation (PFA) SystemDevice
The FARAWAVE™ PFA Catheter will be used to deliver the investigational waveform(s) for the isolation of pulmonary veins and posterior wall in the treatment of paroxysmal and persistent atrial fibrillation. The FARASTAR™ Generator will be used in conjunction with the FARAWAVE™ PFA Catheter to deliver the investigational waveform(s) for the isolation of pulmonary veins and posterior wall in the treatment of paroxysmal and persistent atrial fibrillation. The FARADRIVE™ Steerable Sheath will be used for percutaneous catheter introduction into the chambers of the heart, including the left side of the heart through the interatrial septum.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Device or procedure-related Composite Adverse Events (CAEs)Time frame: Ablation Procedure Day 0 - Day 7; Day 0 - Day 30; Day 0 - Day 60
- Acute Procedural SuccessTime frame: During the Ablation Procedure
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Klinicki Bolnicki Centar Split
Split, Croatia · Recruiting
Na Homolce Hospital
Prague, Czechia · Recruiting
Queen Mary Hospital
Hong Kong, Hong Kong · Recruiting
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.